Tenaya Therapeutics: 2026 as a Pivotal Year for TN-201 and TN-401 Clinical Readouts and Regulatory De-Risking Supporting a Buy Rating
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Joseph Pantginis has maintained a Buy rating on Tenaya Therapeutics, setting a price target of $3.00. He emphasizes 2026 as a crucial year for the company's TN-201 and TN-401 gene therapy programs, with key clinical and regulatory milestones expected to clarify the company's value. Pantginis highlights upcoming data releases and regulatory plans that position Tenaya for late-stage development, supported by a strong cash position of approximately $100 million. Morgan Stanley also maintains a Buy rating with a $2.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments